SCM
ACRS icon

Sterling Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Sterling Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.63K Sell
686
-2,351
-77% -$10.5K ﹤0.01% 2781
2026
Q1 		$11.4K Sell
3,037
-2,251
-43% -$7.59K ﹤0.01% 2302
2025
Q4 		$15.9K Sell
5,288
-692
-12% -$1.75K ﹤0.01% 2354
2025
Q3 		$11.4K Buy
5,980
+3,529
+144% +$6.15K ﹤0.01% 2422
2025
Q2 		$3.48K Buy
+2,451
New +$3.32K ﹤0.01% 2711

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Sterling Capital Management's ACRS Position: Q2 2026 in Review

Sterling Capital Management reduced its Aclaris Therapeutics (ACRS) stake by 77% in Q2 2026, selling an estimated $10.5K and leaving 686 shares worth $3.63K. The position accounts for ﹤0.01% of the portfolio, ranked #2781.

Sterling Capital Management first reported a position in ACRS in Q2 2025 and has held it in 5 quarters since. The position peaked at $15.9K in Q4 2025. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Sterling Capital Management held 686 shares of Aclaris Therapeutics worth $3.63K as of Q2 2026.
  • Sterling Capital Management sold 2,351 Aclaris Therapeutics shares in Q2 2026, an estimated $10.5K.
  • Aclaris Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2781 holding.
  • Sterling Capital Management first reported a position in Aclaris Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Sterling Capital Management's Aclaris Therapeutics position peaked at $15.9K in Q4 2025.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.